TITLE

Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia

AUTHOR(S)
Flasshove, M.; Meusers, P.; Schütte, J.; Noppeney, R.; Beelen, D. W.; Sohrab, S.; Roggenbuck, U.; Kemmeries, G.; Brittinger, G.; Seeber, S.; Scheulen, M. E.
PUB. DATE
October 2000
SOURCE
Annals of Hematology;Oct2000, Vol. 79 Issue 10, p533
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
We treated 153 patients with de novo acute myeloid leukemia (AML) with two induction courses of conventional-dose cytosine arabinoside (ara-C) and idarubicin (AIDA) followed by either a third course of AIDA, high-dose ara-C or bone-marrow transplantation. The complete remission (CR) rate for all patients was 63.4%, with a higher CR rate for patients with a normal (versus unfavorable) karyotype (73.2% vs 52.5%;P=0.038). The probability of overall survival (OS) was 30.7% after 5 years (26.3% after 7 years). Improved OS at 5 years could be observed for patients up to 50 years old versus patients older than 50 years of age (37.6% vs 19.9%;P=0.001) and patients with a normal (versus unfavorable) karyotype (42.9% vs 14.1%;P=0.0016). Disease-free survival (DFS) after 5 years was 33.2% for all 97 CR patients and was significantly better for patients with a normal (versus unfavorable) karyotype (44.3% vs 12.3%;P=0.003). Multivariate analysis revealed that the age for OS (P<0.02) and the karyotype for both OS (P<0.03) and DFS (P<0.05) were independent prognostic factors. In conclusion, AIDA is an effective and well-tolerated induction regimen (even in elderly patients) with a 5-year survival of more than 30% when combined with ara-C-containing postremission therapy. The karyotype is the most powerful prognostic factor for predicting the outcome of patients treated with this protocol.
ACCESSION #
15684644

 

Related Articles

  • Somatic SETBP1 mutations in myeloid malignancies. Makishima, Hideki; Yoshida, Kenichi; Nguyen, Nhu; Przychodzen, Bartlomiej; Sanada, Masashi; Okuno, Yusuke; Ng, Kwok Peng; Gudmundsson, Kristbjorn O; Vishwakarma, Bandana A; Jerez, Andres; Gomez-Segui, Ines; Takahashi, Mariko; Shiraishi, Yuichi; Nagata, Yasunobu; Guinta, Kathryn; Mori, Hiraku; Sekeres, Mikkael A; Chiba, Kenichi; Tanaka, Hiroko; Muramatsu, Hideki // Nature Genetics;Aug2013, Vol. 45 Issue 8, p942 

    Here we report whole-exome sequencing of individuals with various myeloid malignancies and identify recurrent somatic mutations in SETBP1, consistent with a recent report on atypical chronic myeloid leukemia (aCML). Closely positioned somatic SETBP1 mutations encoding changes in Asp868, Ser869,...

  • A new player SETs in myeloid malignancy. Trimarchi, Thomas; Ntziachristos, Panagiotis; Aifantis, Iannis // Nature Genetics;Aug2013, Vol. 45 Issue 8, p846 

    Recent studies have identified recurrent mutations in SETBP1, the gene that encodes SET-binding protein 1, in several types of myeloid malignancies, including chronic myeloid and acute myeloid leukemias. The identified mutations frequently target the SKI-homologous domain, although the exact...

  • Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia. Lewis, I D; Haylock, D N; Moore, S; To, L B; Hughes, T P // Leukemia (08876924);Apr97, Vol. 11 Issue 4, p581 

    Manipulation of autologous bone marrow cells (BM) for transplantation in chronic myeloid leukemia (CML) to enrich for normal cells is a novel approach that may improve survival for patients not suitable for allogeneic transplantation. Limitations of this technique include the reported low...

  • Value of routine 'day 14' marrow exam in newly diagnosed AML. Yezefski, T; Xie, H; Walter, R; Pagel, J; Becker, P S; Hendrie, P; Sandhu, V; Shannon-Dorcy, K; Abkowitz, J; Appelbaum, F R; Estey, E // Leukemia (08876924);Jan2015, Vol. 29 Issue 1, p247 

    A letter to the editor is presented in which the value of routine 'day 14' marrow exam in newly diagnosed acute myeloid leukemia (AML) is being discussed.

  • The role of bone marrow transplantation in acute promyelocytic leukemia. Nabhan, C; Mehta, J; Tallman, M S // Bone Marrow Transplantation;8/1/2001, Vol. 28 Issue 3, p219 

    Acute promyelocytic leukemia (APL) is characterized by a specific gene rearrangement and the generation of the PML-RARα fusion transcript which results from a translocation between chromosomes 15 and 17. Targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy...

  • Detection of CBFβ/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Elmaagacli, A H; Beelen, D W; Kroll, M; Trzensky, S; Stein, C; Schaefer, U W // Bone Marrow Transplantation;1/15/98, Vol. 21 Issue 2, p159 

    We evaluated the occurrence of the CBFβ/MYH11 fusion transcripts by PCR analysis in 10 patients with inv(16)(p13;q22) acute myeloid leukemia (AML) who underwent allogeneic bone marrow transplantation (BMT) (n = 5), peripheral blood progenitor cell transplantation (PBPCT) (n = 3), or...

  • Loss of sex chromosome in acute myeloid leukemia. Bakshi, Sonal R.; Kakadia, Purvi M.; Brahmbhatt, Manisha M.; Trivedi, Pina J.; Rawal, Shwetal M.; Bhatt, Samarth S.; Parikh, Bharat J.; Patel, Kirti M.; Shukla, Shilin N.; Shah, Pankaj M. // Indian Journal of Human Genetics;Jan-Jun2004, Vol. 10 Issue 1, p22 

    Loss of sex chromosomes has been reported in normal and malignant marrows and its frequency increases with age in both situations. It is not clear whether the sex chromosome loss is a critical mutational event for neoplastic transformation or a genetic change related to ageing. The present study...

  • Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. O'Malley, Dennis P.; Orazi, Attilio; Mingsheng Wang; Liang Cheng // Modern Pathology;Dec2005, Vol. 18 Issue 12, p1562 

    Neoplastic myeloid proliferations are seen in the spleens of some patients with acute and chronic myeloproliferative disorders. Both acute myeloid leukemia (AML) and chronic myeloproliferative disorders have a variety of underlying cytogenetic defects that can be evaluated by loss of...

  • ACUTE MYELOMONOCYTIC LEUKEMIA WITH EOSINOPHILIA -- CASE REPORT. P., Thanaseelan; A., Wan Zaidah; H., Rosline // Malaysian Journal of Medical Sciences;Jan2007 Supplement, Vol. 14, p283 

    Introduction: Distinct subset of patients with acute myelomonocytic leukemia associated with abnormal bone marrow eosinophilic precursors has been identified as AML M4 with eosinophilia (AML M4(eo)). This category includes 6% of patients with AML and around 20% of AML M4. It is defined by the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics